Shanghai HeartCare Medical Technology Corporation Limited

Shanghai HeartCare Medical Technology Corporation Limited is a China-based neuro-interventional medical device pioneer aiming to redefine the therapeutic and preventive paradigm of stroke. The company focuses on reducing the mortality rate and improving stroke prognosis globally through the commercialization of innovative product candidates. With a broad portfolio of 23 commercialized products and candidates covering the neurointerventional market, including ischemic and hemorrhagic stroke treatments, the company aims to address the under-penetrated market. Notably, Shanghai HeartCare has obtained NMPA approvals for four ischemic stroke treatment devices, forming a complete product suite for stent retrieving thrombectomy procedures, and plans to commercialize nine late-stage product candidates in 2021 and 10 earlier-stage candidates between 2022 and 2025. With the introduction of the global-first sirolimus intracranial drug-eluting balloon catheter, the company is expanding its offerings for the unmet needs of stroke patients. This commitment to innovation places Shanghai HeartCare at the forefront of the neuro-interventional device revolution.